| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Lobular | 17 | 2023 | 611 | 2.530 |
Why?
|
| Breast Neoplasms | 68 | 2024 | 15694 | 2.120 |
Why?
|
| Carcinoma in Situ | 9 | 2023 | 487 | 1.220 |
Why?
|
| Carcinoma, Ductal, Breast | 14 | 2021 | 1216 | 1.050 |
Why?
|
| Phlebotomy | 2 | 2019 | 26 | 0.840 |
Why?
|
| Hyperplasia | 5 | 2018 | 557 | 0.810 |
Why?
|
| Ambulatory Care Facilities | 2 | 2019 | 289 | 0.730 |
Why?
|
| Amyloidosis | 2 | 2020 | 176 | 0.670 |
Why?
|
| Carcinoma, Papillary | 8 | 2018 | 584 | 0.670 |
Why?
|
| Hemangiosarcoma | 2 | 2021 | 234 | 0.650 |
Why?
|
| Breast | 11 | 2022 | 1344 | 0.640 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2021 | 388 | 0.640 |
Why?
|
| User-Computer Interface | 1 | 2019 | 286 | 0.630 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2024 | 1215 | 0.620 |
Why?
|
| Waiting Lists | 1 | 2019 | 263 | 0.620 |
Why?
|
| Clinical Laboratory Services | 1 | 2018 | 42 | 0.620 |
Why?
|
| Breast Neoplasms, Male | 6 | 2018 | 229 | 0.600 |
Why?
|
| Pathology, Clinical | 1 | 2018 | 152 | 0.580 |
Why?
|
| Ultrasonography, Mammary | 6 | 2021 | 380 | 0.520 |
Why?
|
| Adenomyoepithelioma | 1 | 2014 | 9 | 0.520 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 915 | 0.480 |
Why?
|
| Genes, erbB-2 | 4 | 2009 | 229 | 0.480 |
Why?
|
| Carcinoma | 6 | 2024 | 2578 | 0.470 |
Why?
|
| Mammography | 9 | 2018 | 1010 | 0.460 |
Why?
|
| Pathology | 1 | 2014 | 101 | 0.450 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2008 | 436 | 0.420 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 980 | 0.420 |
Why?
|
| Pregnancy Complications, Neoplastic | 4 | 2010 | 222 | 0.410 |
Why?
|
| Immunohistochemistry | 14 | 2018 | 7548 | 0.410 |
Why?
|
| Papilloma | 3 | 2013 | 74 | 0.410 |
Why?
|
| Referral and Consultation | 2 | 2014 | 899 | 0.400 |
Why?
|
| Breast Carcinoma In Situ | 2 | 2023 | 14 | 0.390 |
Why?
|
| Quality Improvement | 1 | 2018 | 851 | 0.380 |
Why?
|
| Female | 75 | 2024 | 141928 | 0.380 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 4 | 2008 | 674 | 0.370 |
Why?
|
| Receptor, ErbB-2 | 8 | 2014 | 2518 | 0.350 |
Why?
|
| Lymphatic Metastasis | 14 | 2022 | 4844 | 0.350 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 2138 | 0.340 |
Why?
|
| Biopsy, Needle | 6 | 2006 | 1363 | 0.330 |
Why?
|
| Patient Safety | 1 | 2014 | 649 | 0.320 |
Why?
|
| Biomarkers, Tumor | 21 | 2024 | 10331 | 0.310 |
Why?
|
| Humans | 85 | 2024 | 261506 | 0.300 |
Why?
|
| Middle Aged | 52 | 2021 | 86204 | 0.300 |
Why?
|
| Receptors, Estrogen | 6 | 2014 | 2086 | 0.300 |
Why?
|
| Langer-Giedion Syndrome | 2 | 2024 | 21 | 0.290 |
Why?
|
| Hair Diseases | 2 | 2024 | 43 | 0.290 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 383 | 0.290 |
Why?
|
| Estrogen Receptor beta | 1 | 2007 | 155 | 0.280 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2009 | 2232 | 0.280 |
Why?
|
| Fingers | 2 | 2024 | 120 | 0.270 |
Why?
|
| Apocrine Glands | 2 | 2002 | 14 | 0.270 |
Why?
|
| Cystatins | 1 | 2005 | 15 | 0.260 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2005 | 26 | 0.260 |
Why?
|
| Adult | 51 | 2021 | 77950 | 0.260 |
Why?
|
| Receptors, Progesterone | 4 | 2014 | 1392 | 0.260 |
Why?
|
| GATA3 Transcription Factor | 2 | 2024 | 146 | 0.260 |
Why?
|
| Microdissection | 1 | 2005 | 86 | 0.250 |
Why?
|
| Nose | 2 | 2024 | 192 | 0.250 |
Why?
|
| Myoma | 1 | 2004 | 9 | 0.250 |
Why?
|
| Epithelioid Cells | 1 | 2004 | 43 | 0.250 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2022 | 882 | 0.250 |
Why?
|
| Adenoids | 1 | 2024 | 9 | 0.240 |
Why?
|
| Sentinel Lymph Node Biopsy | 5 | 2005 | 1415 | 0.240 |
Why?
|
| Lipoma | 1 | 2004 | 89 | 0.230 |
Why?
|
| Precancerous Conditions | 2 | 2018 | 1058 | 0.230 |
Why?
|
| Phyllodes Tumor | 2 | 2022 | 62 | 0.230 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2024 | 84 | 0.230 |
Why?
|
| Mastectomy | 8 | 2018 | 1534 | 0.220 |
Why?
|
| Aged | 40 | 2021 | 70117 | 0.220 |
Why?
|
| Ki-67 Antigen | 5 | 2023 | 666 | 0.220 |
Why?
|
| Estrogen Receptor alpha | 1 | 2007 | 701 | 0.210 |
Why?
|
| Apolipoproteins | 1 | 2002 | 75 | 0.210 |
Why?
|
| SOXE Transcription Factors | 1 | 2022 | 29 | 0.210 |
Why?
|
| Immunoenzyme Techniques | 6 | 2005 | 1165 | 0.200 |
Why?
|
| Nevus | 1 | 2021 | 107 | 0.190 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2001 | 82 | 0.190 |
Why?
|
| Membrane Transport Proteins | 1 | 2002 | 244 | 0.190 |
Why?
|
| Metaplasia | 1 | 2002 | 383 | 0.190 |
Why?
|
| Repressor Proteins | 3 | 2024 | 1664 | 0.180 |
Why?
|
| Retrospective Studies | 25 | 2022 | 37905 | 0.180 |
Why?
|
| Diagnosis, Differential | 8 | 2021 | 4744 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 9 | 2021 | 3981 | 0.180 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2024 | 421 | 0.180 |
Why?
|
| Chondrosarcoma | 1 | 2022 | 216 | 0.180 |
Why?
|
| Computer Systems | 1 | 2019 | 106 | 0.180 |
Why?
|
| Receptor, Notch1 | 1 | 2021 | 218 | 0.170 |
Why?
|
| Aged, 80 and over | 22 | 2021 | 29902 | 0.170 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2024 | 489 | 0.170 |
Why?
|
| Mesonephros | 1 | 1998 | 6 | 0.170 |
Why?
|
| Cadherins | 1 | 2002 | 660 | 0.170 |
Why?
|
| Mastectomy, Segmental | 3 | 2010 | 1026 | 0.170 |
Why?
|
| Genital Neoplasms, Male | 1 | 1998 | 44 | 0.160 |
Why?
|
| Glycoproteins | 1 | 2002 | 747 | 0.160 |
Why?
|
| Follow-Up Studies | 8 | 2018 | 14889 | 0.160 |
Why?
|
| Adnexal Diseases | 1 | 1998 | 30 | 0.160 |
Why?
|
| Seminal Vesicles | 1 | 1998 | 152 | 0.160 |
Why?
|
| Automation, Laboratory | 1 | 2018 | 27 | 0.160 |
Why?
|
| Chemotherapy, Adjuvant | 10 | 2010 | 3890 | 0.160 |
Why?
|
| Hemangiopericytoma | 1 | 1998 | 56 | 0.160 |
Why?
|
| Image-Guided Biopsy | 2 | 2018 | 327 | 0.160 |
Why?
|
| Neoplasms | 2 | 2014 | 15193 | 0.150 |
Why?
|
| Cell Nucleus | 5 | 2011 | 1620 | 0.150 |
Why?
|
| Axilla | 8 | 2021 | 902 | 0.150 |
Why?
|
| Prognosis | 13 | 2023 | 21713 | 0.150 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2018 | 145 | 0.140 |
Why?
|
| Biopsy, Large-Core Needle | 2 | 2014 | 134 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 810 | 0.140 |
Why?
|
| Radiography | 2 | 2014 | 1904 | 0.140 |
Why?
|
| History, 21st Century | 1 | 2018 | 441 | 0.140 |
Why?
|
| Capecitabine | 1 | 2017 | 388 | 0.140 |
Why?
|
| Lymphoma | 1 | 2004 | 1467 | 0.140 |
Why?
|
| Reproducibility of Results | 4 | 2018 | 6009 | 0.130 |
Why?
|
| Aromatase Inhibitors | 1 | 2018 | 305 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2018 | 574 | 0.130 |
Why?
|
| Skin Neoplasms | 2 | 2022 | 4654 | 0.130 |
Why?
|
| Disease-Free Survival | 7 | 2017 | 10001 | 0.130 |
Why?
|
| Lymph Nodes | 7 | 2021 | 2967 | 0.130 |
Why?
|
| Pathology Department, Hospital | 1 | 2014 | 14 | 0.130 |
Why?
|
| Melanoma | 2 | 2022 | 5317 | 0.120 |
Why?
|
| Osteosarcoma | 1 | 2022 | 929 | 0.120 |
Why?
|
| Multimodal Imaging | 1 | 2018 | 550 | 0.120 |
Why?
|
| Pathology, Surgical | 1 | 2014 | 81 | 0.120 |
Why?
|
| Sarcoma | 2 | 2022 | 1725 | 0.120 |
Why?
|
| Bioengineering | 1 | 2013 | 27 | 0.120 |
Why?
|
| Loss of Heterozygosity | 3 | 2000 | 602 | 0.110 |
Why?
|
| Cold Ischemia | 1 | 2012 | 22 | 0.110 |
Why?
|
| Calcinosis | 2 | 2008 | 423 | 0.110 |
Why?
|
| Diagnostic Errors | 2 | 2014 | 509 | 0.110 |
Why?
|
| Curriculum | 1 | 2018 | 860 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2018 | 7702 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2001 | 2326 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 1299 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2010 | 15862 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 6 | 2009 | 4975 | 0.090 |
Why?
|
| Neoplasm, Residual | 4 | 2014 | 1656 | 0.090 |
Why?
|
| Specimen Handling | 1 | 2012 | 299 | 0.090 |
Why?
|
| Melanocytes | 2 | 2021 | 219 | 0.090 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2010 | 69 | 0.090 |
Why?
|
| Kidney Neoplasms | 2 | 2001 | 3022 | 0.090 |
Why?
|
| Keratins | 3 | 2009 | 330 | 0.090 |
Why?
|
| Mastectomy, Modified Radical | 1 | 2010 | 70 | 0.090 |
Why?
|
| Gene Amplification | 2 | 2010 | 731 | 0.090 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 854 | 0.090 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2003 | 551 | 0.090 |
Why?
|
| Gynecomastia | 1 | 2008 | 13 | 0.090 |
Why?
|
| Bone Neoplasms | 1 | 2022 | 2576 | 0.080 |
Why?
|
| CDX2 Transcription Factor | 1 | 2008 | 37 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 585 | 0.080 |
Why?
|
| Ovarian Neoplasms | 2 | 2004 | 4638 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2017 | 10035 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 5437 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2008 | 27 | 0.080 |
Why?
|
| Inpatients | 1 | 2013 | 678 | 0.080 |
Why?
|
| Genetic Heterogeneity | 1 | 2010 | 318 | 0.080 |
Why?
|
| Breast Diseases | 1 | 2010 | 201 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2008 | 89 | 0.080 |
Why?
|
| Hereditary Sensory and Motor Neuropathy | 2 | 1998 | 37 | 0.080 |
Why?
|
| Neoplasm Staging | 9 | 2018 | 13658 | 0.080 |
Why?
|
| Mucins | 1 | 2008 | 285 | 0.080 |
Why?
|
| Age Factors | 4 | 2009 | 5377 | 0.080 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2010 | 342 | 0.070 |
Why?
|
| Antineoplastic Agents | 4 | 2010 | 14289 | 0.070 |
Why?
|
| Cystatin M | 1 | 2005 | 1 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 3 | 2000 | 3203 | 0.060 |
Why?
|
| Survival Analysis | 6 | 2009 | 9180 | 0.060 |
Why?
|
| Texas | 2 | 2018 | 6311 | 0.060 |
Why?
|
| Disease Progression | 2 | 2008 | 6682 | 0.060 |
Why?
|
| Combined Modality Therapy | 3 | 2011 | 8865 | 0.060 |
Why?
|
| Cystatin C | 1 | 2005 | 54 | 0.060 |
Why?
|
| Male | 15 | 2021 | 123000 | 0.060 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2011 | 716 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 2403 | 0.060 |
Why?
|
| Survival Rate | 5 | 2011 | 12221 | 0.060 |
Why?
|
| Demyelinating Diseases | 2 | 1998 | 77 | 0.060 |
Why?
|
| Physical Examination | 1 | 2006 | 299 | 0.060 |
Why?
|
| Lasers | 1 | 2005 | 198 | 0.060 |
Why?
|
| Treatment Outcome | 9 | 2018 | 32848 | 0.060 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2007 | 690 | 0.060 |
Why?
|
| Proto-Oncogenes | 1 | 2004 | 202 | 0.060 |
Why?
|
| Predictive Value of Tests | 4 | 2006 | 4892 | 0.060 |
Why?
|
| CD3 Complex | 1 | 2004 | 314 | 0.060 |
Why?
|
| Salivary Glands | 1 | 2024 | 130 | 0.060 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 1143 | 0.060 |
Why?
|
| Fibrocystic Breast Disease | 1 | 2003 | 45 | 0.060 |
Why?
|
| Apolipoproteins D | 1 | 2002 | 6 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2009 | 1335 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2005 | 1037 | 0.050 |
Why?
|
| DNA Primers | 1 | 2005 | 1399 | 0.050 |
Why?
|
| Microscopy, Electron | 3 | 1998 | 600 | 0.050 |
Why?
|
| Cell Nucleolus | 1 | 2002 | 89 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2004 | 479 | 0.050 |
Why?
|
| Stereotaxic Techniques | 1 | 2003 | 172 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 1533 | 0.050 |
Why?
|
| Histiocytes | 1 | 2002 | 94 | 0.050 |
Why?
|
| RNA, Neoplasm | 1 | 2005 | 771 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2008 | 1555 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2011 | 2359 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 1547 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 482 | 0.050 |
Why?
|
| Carcinoma, Medullary | 1 | 2003 | 248 | 0.050 |
Why?
|
| Pregnancy | 4 | 2010 | 7573 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 1162 | 0.050 |
Why?
|
| Age of Onset | 1 | 2003 | 827 | 0.050 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2004 | 486 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 1 | 2009 | 1350 | 0.050 |
Why?
|
| Doxorubicin | 4 | 2010 | 3005 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2002 | 652 | 0.050 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2001 | 178 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2005 | 3552 | 0.040 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2002 | 362 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2003 | 1090 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2000 | 575 | 0.040 |
Why?
|
| Fluorouracil | 3 | 2010 | 1944 | 0.040 |
Why?
|
| Antigens, Nuclear | 1 | 1999 | 119 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2002 | 726 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 3639 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2003 | 2341 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 1998 | 169 | 0.040 |
Why?
|
| Peritoneal Neoplasms | 1 | 2004 | 821 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2005 | 6150 | 0.040 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1998 | 195 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2018 | 90 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 6207 | 0.040 |
Why?
|
| Deafness | 1 | 1998 | 82 | 0.040 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2017 | 85 | 0.040 |
Why?
|
| Antibodies, Neoplasm | 1 | 1998 | 259 | 0.040 |
Why?
|
| Roma | 1 | 1996 | 4 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 160 | 0.040 |
Why?
|
| Anthracyclines | 2 | 2010 | 331 | 0.030 |
Why?
|
| Cyclophosphamide | 3 | 2010 | 3001 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1999 | 641 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1996 | 317 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2018 | 597 | 0.030 |
Why?
|
| Sural Nerve | 2 | 1998 | 54 | 0.030 |
Why?
|
| Taxoids | 2 | 2010 | 967 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 4988 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 4971 | 0.030 |
Why?
|
| Laboratories, Hospital | 1 | 2013 | 29 | 0.030 |
Why?
|
| Cell Division | 1 | 1998 | 2489 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2002 | 2022 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2018 | 667 | 0.030 |
Why?
|
| Endometrial Neoplasms | 1 | 2003 | 1341 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 884 | 0.030 |
Why?
|
| Incidence | 1 | 2003 | 5673 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 1996 | 1471 | 0.030 |
Why?
|
| Adolescent | 7 | 2009 | 31252 | 0.030 |
Why?
|
| Goals | 1 | 2013 | 185 | 0.030 |
Why?
|
| Neoplasm Proteins | 2 | 2001 | 3230 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2012 | 136 | 0.030 |
Why?
|
| Young Adult | 3 | 2021 | 21445 | 0.030 |
Why?
|
| Karyotyping | 1 | 2003 | 1022 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 3472 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2018 | 2218 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2017 | 1529 | 0.020 |
Why?
|
| Lymph Node Excision | 2 | 2011 | 1959 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 1742 | 0.020 |
Why?
|
| Polyneuropathies | 1 | 1989 | 28 | 0.020 |
Why?
|
| Bridged-Ring Compounds | 1 | 2010 | 183 | 0.020 |
Why?
|
| Cellulitis | 1 | 2010 | 72 | 0.020 |
Why?
|
| Spinal Nerves | 1 | 1989 | 45 | 0.020 |
Why?
|
| Hereditary Sensory and Autonomic Neuropathies | 1 | 1989 | 10 | 0.020 |
Why?
|
| Ultrasonography | 2 | 2007 | 1863 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2017 | 3842 | 0.020 |
Why?
|
| Cranial Nerve Diseases | 1 | 1989 | 73 | 0.020 |
Why?
|
| Hematoma | 1 | 2010 | 160 | 0.020 |
Why?
|
| Abscess | 1 | 2010 | 177 | 0.020 |
Why?
|
| Postpartum Period | 1 | 2010 | 259 | 0.020 |
Why?
|
| Cytodiagnosis | 1 | 2009 | 220 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 1999 | 3343 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 3719 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2017 | 12873 | 0.020 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2006 | 89 | 0.020 |
Why?
|
| Child | 4 | 2006 | 29154 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 1323 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 2009 | 5112 | 0.020 |
Why?
|
| Epithelium | 1 | 2007 | 720 | 0.020 |
Why?
|
| Clavicle | 1 | 2004 | 65 | 0.020 |
Why?
|
| Reoperation | 1 | 2009 | 1382 | 0.020 |
Why?
|
| Child Development | 1 | 2006 | 255 | 0.020 |
Why?
|
| Lymphatic Irradiation | 1 | 2004 | 133 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2004 | 157 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 980 | 0.010 |
Why?
|
| Keratin-7 | 1 | 2003 | 52 | 0.010 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2003 | 115 | 0.010 |
Why?
|
| Biomarkers | 1 | 2014 | 5047 | 0.010 |
Why?
|
| Gestational Age | 1 | 2006 | 1069 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2006 | 643 | 0.010 |
Why?
|
| Infant | 1 | 1998 | 13310 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2006 | 876 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1998 | 16273 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2003 | 660 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2006 | 2231 | 0.010 |
Why?
|
| Melanins | 1 | 2001 | 50 | 0.010 |
Why?
|
| Decision Making | 1 | 2009 | 1287 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 1546 | 0.010 |
Why?
|
| Time Factors | 1 | 2013 | 12926 | 0.010 |
Why?
|
| Microfilament Proteins | 1 | 2002 | 487 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2004 | 2316 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2009 | 6100 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2006 | 1996 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2011 | 7226 | 0.010 |
Why?
|
| Hearing | 1 | 1998 | 64 | 0.010 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 1998 | 39 | 0.010 |
Why?
|
| Neural Conduction | 1 | 1998 | 112 | 0.010 |
Why?
|
| Carrier State | 1 | 1998 | 90 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1998 | 333 | 0.010 |
Why?
|
| Bulgaria | 1 | 1996 | 5 | 0.010 |
Why?
|
| Founder Effect | 1 | 1996 | 42 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 1756 | 0.010 |
Why?
|
| Biopsy | 2 | 1998 | 3443 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 6869 | 0.010 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 1996 | 122 | 0.010 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2003 | 962 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 1996 | 512 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2006 | 9244 | 0.010 |
Why?
|
| Pedigree | 1 | 1996 | 1890 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1998 | 1910 | 0.010 |
Why?
|
| Risk Factors | 1 | 2009 | 17523 | 0.010 |
Why?
|
| Prealbumin | 1 | 1989 | 37 | 0.010 |
Why?
|
| DNA Probes | 1 | 1989 | 217 | 0.010 |
Why?
|
| Motor Neurons | 1 | 1989 | 138 | 0.010 |
Why?
|
| Central Nervous System Diseases | 1 | 1989 | 129 | 0.010 |
Why?
|
| Genetic Carrier Screening | 1 | 1989 | 92 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2004 | 8873 | 0.000 |
Why?
|
| Europe | 1 | 1989 | 649 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1989 | 1819 | 0.000 |
Why?
|
| Animals | 1 | 2008 | 59536 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 11538 | 0.000 |
Why?
|
| Mutation | 1 | 1989 | 15179 | 0.000 |
Why?
|